Sickle cell anemia is a debilitating genetic condition that affects red blood cells. Traditionally, treatments focused on managing symptoms like pain and preventing complications. But recent years have seen a surge in the development of new therapies that target the underlying causes of the disease.
BMT is a suitable treatment for both cancerous and non-cancerous conditions such as sickle-cell anaemia or thalassemia. Relapse in BMT is less compared to the relapse in chemotherapy and therefore, BMT is a well-preferred treatment for blood cancers. In recent years, haploidentical BMT has been observed to give as good a result as a full-matched BMT. With scientific progress and better drugs, India is achieving the current BMT success rates.
